Atopic Dermatitis/Atopic Eczema – Emerging Therapies – Eucrisa Launch Tracking Wave 3 (US)
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data collected at 1, 6, and 12 months post-commercial launch from surveys of U.S. dermatologists. Along with awareness of, sources of familiarity with, and perceptions related to Eucrisa, the research assesses trial, adoption, and usage, including anticipated future trends, of Eucrisa. We also explore Pfizer’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.
What you will learn in this content:
- What is U.S. dermatologists' awareness of and familiarity with Eucrisa, and what are their perceptions of this product?
- Among prescribers, for which patients are they prescribing Eucrisa, what are the reasons for prescribing, and how satisfied are they with Eucrisa?
- What are the promotional messages and activities that Pfizer is employing in support of the Eucrisa launch?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Eucrisa tracking compared with other recent product launches in the AD market?
Methodology: ~75 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.
Key drugs: Eucrisa
Key companies: Pfizer
Related reports: Atopic Dermatitis | Disease Landscape and Forecast | US/EU/Japan, Atopic Dermatitis | Unmet Need | US/EU, Atopic Dermatitis | Access & Reimbursement | US, Atopic Dermatitis | Access and Reimbursement | EU5, Atopic Dermatitis | Current Treatment | EU5
Table of contents
- Atopic Dermatitis/Atopic Eczema - Emerging Therapies - Eucrisa Launch Tracking Wave 3 (US)
- Key Findings
- Benchmarking Eucrisa Launch Success vs. Other Launched Drugs
- Key Findings
- Prescriber and Nonprescriber Profiles
- Differences Between Eucrisa Prescribers and Nonprescribers
- Differences Between Eucrisa Prescriber and Nonprescriber Profiles
- Eucrisa Awareness and Perceptions
- Unaided and Aided Awareness of Eucrisa
- Awareness of Eucrisa
- Awareness of Eucrisa's Approval for AD
- Awareness of the Administration of Eucrisa
- Estimated Cost of Eucrisa
- Unaided Awareness of Drugs Approved or Launched for the Treatment of Atopic Dermatitis
- Familiarity with Eucrisa
- Familiarity with Eucrisa (mean)
- Sources of Familiarity with Eucrisa
- Initial Reaction to and Interest in Eucrisa
- Initial Reaction to Eucrisa After Viewing Product Profile
- Initial Reaction to Eucrisa After Viewing Product Profile (Mean)
- Level of Interest in Learning More About Eucrisa
- Level of Interest in Learning More About Eucrisa (Mean)
- Impressions of Eucrisa
- Existence of Eucrisa Attributes About Which Dermatologists Were Unaware
- Perceived Uniqueness of Eucrisa
- Perceived Uniqueness of Eucrisa (Mean)
- Perceived Value of Eucrisa Attributes
- Perceived Value of Eucrisa Attributes (Mean)
- Risk-Benefit Ratio of Eucrisa
- Risk-Benefit Ratio of Eucrisa (Mean)
- Aspects of Eucrisa About Which Dermatologists Were Unaware
- Unaided Eucrisa Advantages
- Unaided Eucrisa Disadvantages
- Prescriber and Nonprescriber Profiles
- Unaided and Aided Awareness of Eucrisa
- Eucrisa Trial and Use
- Willingness to Prescribe Eucrisa
- Willingness to Prescribe Eucrisa (Mean)
- Impact of Attributes on Willingness to Prescribe Eucrisa
- Impact of Attributes on Willingness to Prescribe Eucrisa (Mean)
- Number of Patients Currently Receiving Eucrisa
- Agents Currently Prescribed to AD Patients
- Eucrisa Patient Volume
- Mean Eucrisa Patient Volume
- Timing of Eucrisa Prescription
- Eucrisa Discontinuation Rate
- Length of Time on Eucrisa Before Discontinuation
- Reasons for Discontinuing Eucrisa
- Agents Switched to by Discontinued Eucrisa Patients
- Eucrisa Patients by Disease Severity
- Origination of Patients Treated with Eucrisa
- Replaced Therapies for Patients Switched to Eucrisa
- Background Therapies for Patients Prescribed Adjunct Eucrisa
- Reasons for Switching to Eucrisa from Previous Therapy
- Reasons Patients Initiated or Switched to Eucrisa
- Rate of Eucrisa Usage in Pediatric Patients
- Reasons for Not Yet Prescribing Eucrisa
- Anticipated Eucrisa Use
- Number of Patient Inquiries for Eucrisa
- Results of Specific Patient Inquiries for Eucrisa
- Nonprescriber Timeline for Eucrisa Trial
- Candidates for Eucrisa by AD Patient Population
- Candidates for Eucrisa by Treatment History
- Therapies Eucrisa Is Likely to Replace
- Reasons for Not Prescribing Eucrisa More
- Percentage of AD Patients Expected to Receive Drug Treatment in Next Six Months
- Agents that Dermatologists Expect to Prescribe to AD Patients in Next Six Months
- Eucrisa Performance on Key Attributes
- Overall Satisfaction with Eucrisa
- Overall Satisfaction with Eucrisa (Mean)
- Ease of Eucrisa's Managed Care Approval Process
- Ease of Eucrisa's Managed Care Approval Process (Mean)
- Requirements for Eucrisa's Managed Care Approval
- Eucrisa Performance on Key Attributes (All Respondents)
- Eucrisa Performance on Key Attributes (Mean; All Respondents)
- Eucrisa Performance on Key Attributes (Prescribers)
- Eucrisa Performance on Key Attributes (Nonprescribers)
- Eucrisa Performance on Key Attributes (Prescribers v Nonprescribers)
- Eucrisa Performance on Key Attributes (Mean; Prescribers v Nonprescribers)
- Willingness to Prescribe Eucrisa
- Effectiveness of Face-to-Face Detailing for Eucrisa
- Eucrisa Sales Representative Frequency and Reach
- Duration Since Last Contact with Eucrisa Sales Representative
- Frequency of Visits by Eucrisa Sales Representative
- Satisfaction with Eucrisa Sales Representative
- Eucrisa Sales Representative Performance
- Eucrisa Sales Representative Performance (Mean)
- Eucrisa Message Recall
- Message Recall During Recent Detail
- Treatment Positioned Against Eucrisa by Representative
- Materials Used by Eucrisa Representative During Visit
- Frequency of Eucrisa Representative Providing Samples During Visit
- Eucrisa Sales Representative Frequency and Reach
- Appendix
- Primary Market Research
- Age Distribution of AD Patients Under Management
- Desire to Receive Samples Among Physicians Who Reported Not Receiving Eucrisa Samples During Visit
- Physician Reported Utilization of Eucrisa Samples
- Physician Reported Frequency of Representative Suggesting Ideal Patient Type for Eucrisa (in last month)
- Abbreviations
- Primary Market Research
- Key Findings
Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.
In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry
He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.
Emily Schriner, M.P.H., is a business insights analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information. Ms. Schriner earned her master’s degree in public health in nutrition at West Chester University of Pennsylvania. She completed an internship at Nemours Health Network in Wilmington, Delaware.